HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Supplemental Data All Versions of this Article: clinchem.2008.111989v1 54/12/1961    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by deWilde, A. Articles by Hahn, S. H. Search for Related Content PubMed PubMed Citation Articles by deWilde, A. Articles by Hahn, S. H.

Tryptic Peptide Analysis of Ceruloplasmin in Dried Blood Spots Using Liquid Chromatography–Tandem Mass Spectrometry: Application to Newborn Screening

¹ Seattle Children’s Hospital Research Institute, Seattle, WA; ² Department of Chemistry, University of Washington, Seattle, WA; ³ Department of Pediatrics, Division of Genetics and Developmental Medicine, University of Washington School of Medicine, Seattle, WA.

^aAddress correspondence to this author at: Department of Pediatrics, University of Washington School of Medicine, 4800 Sand Point Way, B6594, Seattle, WA. Fax 206-987-5329; e-mail sihahn{at}u.washington.edu.

Background: Newborn screening to identify infants with treatable congenital disorders is carried out worldwide. Recent tandem mass spectrometry (MS/MS) applications have markedly expanded the ability to screen for >50 metabolic diseases with a single dried blood spot (DBS). The feature that makes metabolic disorders particularly amenable to screening is the presence of specific small-molecule metabolites. Many treatable disorders such as Wilson disease, however, are characterized by absent or diminished large proteins in plasma or within circulating blood cells, for which there are currently no cost-effective screening methods.

Methods: We developed an assay for quantifying ceruloplasmin (CP) in DBS for newborn screening of Wilson disease. CP-specific peptides from DBS samples digested by trypsin were quantified using isotopically labeled peptide internal standards and liquid chromatography–triple quadrupole mass spectrometry (LC-MS/MS).

Results: The calibration curve was linear from 20 to 95 mg/dL (200–950 mg/L). Intraassay imprecision (mean CV) for CP concentrations of 25, 35, and 55 mg/dL (250, 350, and 550 mg/L) was 9.2%, 10.7%, and 10.2%, respectively. Interassay imprecision for 19 different batches was 8.9%, 5.8%, and 6.9%. A method comparison study on previously tested patient samples for CP gave comparable results with lower limit of quantification, around 0.7 mg/dL (7 mg/L).

Conclusions: Our study supports that newborn screening for Wilson disease is feasible using LC-MS/MS assay for CP quantification in DBS after tryptic digestion. This approach should be applicable to newborn screening for other treatable genetic conditions, such as primary immunodeficiencies, that have large proteins as biomarkers.

The following articles in journals at HighWire Press have cited this article:

				F. Boemer, O. Ketelslegers, J.-M. Minon, V. Bours, and R. Schoos In Reply Clin. Chem., June 1, 2009; 55(6): 1244 - 1245. [Full Text] [PDF]

				W. A. Gahl Newborn Screening for Wilson Disease: Does Liquid Chromatography-Tandem Mass Spectrometry Provide the Solution? Clin. Chem., December 1, 2008; 54(12): 1941 - 1942. [Full Text] [PDF]